Anne Vincent-Salomon Selected Research

Trastuzumab (Herceptin)

4/2022	Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.
12/2021
2/2020	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
1/2018	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
10/2010	Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.
1/2010	Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
11/2007	HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.
3/2007	[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
11/2006	High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.
5/2004	Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Vincent-Salomon Research Topics

Disease

113	Neoplasms (Cancer) 11/2022 - 03/2002
95	Breast Neoplasms (Breast Cancer) 04/2022 - 03/2002
25	Neoplasm Metastasis (Metastasis) 04/2021 - 03/2002
19	Carcinoma (Carcinomatosis) 01/2022 - 11/2003
17	Triple Negative Breast Neoplasms 12/2021 - 01/2013
5	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 01/2004
5	Lymphatic Metastasis 01/2020 - 03/2002
3	Carcinogenesis 05/2021 - 12/2015
3	Ductal Carcinoma 11/2020 - 09/2010
3	Pathologic Complete Response 11/2019 - 06/2012
3	Residual Neoplasm 01/2018 - 01/2004
2	Lobular Carcinoma 01/2022 - 07/2013
2	Disease Progression 01/2021 - 01/2010
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 11/2007
2	Metaplasia 01/2017 - 03/2015
2	Papillary Carcinoma 12/2014 - 02/2012
2	Genomic Instability 01/2013 - 11/2009
2	Lymphoma (Lymphomas) 03/2012 - 09/2006
2	Infections 09/2010 - 09/2006
2	B-Cell Lymphoma (Lymphoma, B Cell) 09/2010 - 07/2006
2	Neoplasm Micrometastasis 03/2008 - 08/2005
1	Necrosis 01/2022
1	Fistula 01/2022

Drug/Important Bio-Agent (IBA)

24	Phenobarbital (Luminal)FDA Link 11/2022 - 12/2005
22	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2003
17	Biomarkers (Surrogate Marker)IBA 11/2021 - 11/2008
13	RNA (Ribonucleic Acid)IBA 10/2021 - 06/2007
13	Estrogen ReceptorsIBA 01/2021 - 02/2004
11	Trastuzumab (Herceptin)FDA Link 04/2022 - 12/2003
11	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2007
8	Hormones (Hormone)IBA 04/2021 - 11/2003
8	Biological ProductsIBA 01/2019 - 12/2005
6	Monoclonal AntibodiesIBA 12/2019 - 12/2003
5	Circulating Tumor DNAIBA 01/2022 - 01/2016
5	Indicators and Reagents (Reagents)IBA 05/2021 - 11/2003
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 02/2016
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 03/2005
4	Cadherins (E-Cadherin)IBA 01/2022 - 07/2013
4	palbociclibIBA 01/2022 - 01/2020
4	CollagenIBA 01/2022 - 10/2015
4	Metalloproteases (Metalloproteinases)IBA 01/2021 - 05/2014
4	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2021 - 05/2014
4	Keratins (Keratin)IBA 01/2014 - 06/2002
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 06/2010
3	AntibodiesIBA 12/2021 - 07/2013
3	Small Interfering RNA (siRNA)IBA 01/2019 - 10/2009
3	ChromatinIBA 01/2019 - 04/2015
3	Oncogene Proteins (Oncogene Protein)IBA 10/2018 - 03/2007
3	AnthracyclinesIBA 01/2018 - 04/2002
3	Epithelial Cell Adhesion MoleculeIBA 01/2017 - 01/2004
3	Neoplasm Antigens (Tumor Antigens)IBA 04/2014 - 01/2003
3	AntigensIBA 09/2010 - 01/2003
3	Rituximab (Mabthera)FDA Link 06/2009 - 07/2006
3	human ERBB2 proteinIBA 01/2008 - 05/2004
2	Aromatase InhibitorsIBA 01/2022 - 01/2019
2	Epidermal Growth Factor (EGF)IBA 12/2021 - 01/2016
2	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2020
2	CytokinesIBA 05/2021 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 07/2007
2	EnzymesIBA 11/2020 - 01/2019
2	MicroRNAs (MicroRNA)IBA 02/2020 - 12/2014
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 02/2009
2	Dihydrotachysterol (AT 10)IBA 01/2020 - 03/2007
2	CortactinIBA 12/2018 - 05/2014
2	Peptide Hydrolases (Proteases)FDA Link 12/2018 - 10/2015
2	Protein Isoforms (Isoforms)IBA 11/2018 - 06/2004
2	Androgen Receptors (Androgen Receptor)IBA 08/2018 - 01/2018
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018 - 03/2012
2	ParaffinIBA 01/2018 - 11/2007
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2017 - 09/2008
2	ClaudinsIBA 01/2017 - 03/2015
2	Mitochondrial DNA (mtDNA)IBA 01/2016 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2012 - 07/2004
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2012 - 07/2004
2	ErbB Receptors (EGF Receptor)IBA 10/2010 - 11/2003
2	FicollIBA 02/2004 - 01/2004
1	Etoposide (VP 16)FDA LinkGeneric 04/2022
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 04/2022
1	NucleotidesIBA 01/2022
1	Letrozole (Femara)FDA LinkGeneric 01/2022
1	OligonucleotidesIBA 01/2022
1	Codon (Codons)IBA 01/2022
1	Untranslated RNA (Noncoding RNA)IBA 05/2021
1	Progesterone FDA LinkGeneric 04/2021
1	Estrogens (Estrogen)FDA Link 04/2021
1	methylamphotericin B (AME)IBA 01/2021
1	MyogeninIBA 01/2021
1	dabrafenibIBA 01/2021
1	DesminIBA 01/2021

Therapy/Procedure

39	Therapeutics 01/2022 - 11/2003
24	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
12	Neoadjuvant Therapy 12/2021 - 11/2008
8	Radiotherapy 01/2022 - 12/2005
4	Precision Medicine 11/2021 - 04/2016
4	Immunotherapy 02/2021 - 01/2003
4	Segmental Mastectomy (Lumpectomy) 11/2009 - 03/2002
2	Aftercare (After-Treatment) 11/2019 - 04/2002
2	Lymph Node Excision (Lymph Node Dissection) 01/2017 - 03/2002
2	Mastectomy (Mammectomy) 12/2003 - 03/2002